|Day Low/High||278.17 / 294.99|
|52 Wk Low/High||215.78 / 374.99|
Too many turn bearish too quickly just because they can't find any entry points.
The S&P 500 clinched a new closing high for 2016 as crude closed above $50 a barrel on Tuesday.
Shares of Biogen and Alexion Pharmaceuticals took a hit Tuesday after their promising new products failed clinical trials.
U.S. indices are up as oil continues its climb past $50 a barrel.
We've seen yet another disaster in Biogen's history of overpromising and under-delivering.
Stocks compounded early-week gains, helped along by a less-hawkish Federal Reserve and crude gains.
These mid-caps would do well by themselves, but could tempt bigger companies.
The essence of sloppiness is to let it all ride, so look at your portfolio and decide what has moved too much and what you should take off.
It is hard to see much growth in the market overall, until earnings growth returns.
After an asset price drop, large pharmaceutical companies are looking for strategic purchases.
BIIB could be headed above $300 over the intermediate term.
Biogen is a biotech company focused on treating a host of diseases.
U.S. stocks were mixed as a slew of earnings report kept investors busy.
U.S. stocks slip as oil prices lose steam in Thursday's trading session
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
With Pfizer deal dead, Allergan is ready to go shopping.
The lack of fear, by way of the VIX, speaks volumes about where the market is headed.
TheStreet's Jim Cramer is on the floor of the NYSE talking MLB's Opening Day and answering social media questions.
The biotech company's shares remain range-bound, but a fresh rally appears to be brewing.
At the very least, move those stop loss levels in very close on long positions.
The group rallied yesterday, but it's still not out of the woods.
The short- and longer-term trends are both bearish here as biotechs struggle.
TheStreet’s Jim Cramer discussed the bear market in biotechs while answering viewer questions from social media on Friday.